HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 290/4/H1706    most recent 00885.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Krum, H. Articles by Esler, M. Search for Related Content PubMed PubMed Citation Articles by Krum, H. Articles by Esler, M.

Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension

¹National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics, Monash University, ²Baker Heart Research Institute, and ³St Vincent's Institute of Medical Research and Department of Medicine, University of Melbourne, Melbourne, Australia

Submitted 18 August 2005 ; accepted in final form 8 November 2005

It has long been proposed that the renin-angiotensin system exerts a stimulatory influence on the sympathetic nervous system, including augmentation of central sympathetic outflow and presynaptic facilitation of norepinephrine release from sympathetic nerves. We tested this proposition in 19 patients with essential hypertension, evaluating whether the angiotensin receptor blockers (ARBs) eprosartan and losartan had identifiable antiadrenergic properties. This was done in a prospective, randomized, three-way placebo-controlled study of crossover design. Patients were randomized to 600 mg of eprosartan daily, 50 mg of losartan daily, or placebo. The treatment period was 4 wk, with 2-wk washout periods. Multiunit firing rates in efferent sympathetic nerves distributed to skeletal muscle vasculature (muscle sympathetic nerve activity, MSNA) were measured with microneurography, testing whether ARBs inhibit central sympathetic outflow. In parallel, isotope dilution methodology was used to measure whole body norepinephrine spillover to plasma. Mean blood pressure on placebo was 151/98 mmHg, with both ARBs causing reductions of 11 mmHg systolic and 6 mmHg diastolic pressure, placebo corrected. Both MSNA [35 ± 12 bursts/min (mean ± SD) on placebo] and whole body norepinephrine spillover [366 ± 247 ng/min] were unchanged by ARB administration, indicating that the ARBs did not materially inhibit central sympathetic outflow or act presynaptically to reduce norepinephrine release at existing rates of nerve firing. These findings contrast with the easily demonstrable reduction in sympathetic nervous activity produced by antihypertensive drugs of the imidazoline-binding class, which are known to act within the brain to inhibit sympathetic nervous outflow. We conclude that sympathetic nervous inhibition is not a major component of the blood pressure-lowering action of ARBs in essential hypertension.

sympathetic nervous system; angiotensin receptor blocker

This article has been cited by other articles:

				A. J. King, M. Novotny, G. M. Swain, and G. D. Fink Whole body norepinephrine kinetics in ANG II-salt hypertension in the rat Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1262 - R1267. [Abstract] [Full Text] [PDF]

				M. P. Schlaich, E. A. Lambert, P. A. Sobotka, G. W. Lambert, and M. D. Esler Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment Hypertension, May 1, 2007; 49(5): e27 - e27. [Full Text] [PDF]

				R. M. Brothers, M. L. Haslund, D. W. Wray, P. B. Raven, and M. Sander Exercise-induced inhibition of angiotensin II vasoconstriction in human thigh muscle J. Physiol., December 1, 2006; 577(2): 727 - 737. [Abstract] [Full Text] [PDF]